BWX Technologies, Inc.
Cost-plus + fixed-price government defense/energy contracts (Naval Nuclear Propulsion Program prime supplier) plus commercial nuclear components, fuel handling, and isotope product sales; long-cycle, backlog-driven, recurring.
The thesis on this name
State of Nuclear Energy
A cash-flowing component monopoly mispriced as a story stock. Unlike the pre-revenue SMR names, BWXT has a $8.65B backlog (+50% YoY) anchored by U.S. Navy propulsion, guided ~13%/17% rev/EPS CAGRs 2025-28, and is the only at-scale North American maker of nuclear components and fuel. The microreactor + TRISO leg is upside you get without paying a pure-play SMR multiple.
State of Nuclear Energy
Buy the cash-flowing nuclear-component monopoly mispriced like a story stock — $8.65B Navy-anchored backlog, ~13%/17% rev/EPS CAGRs, with microreactor + TRISO/HALEU as free advanced-nuclear optionality.
State of Nuclear Energy
The only large-scale North American producer of naval reactor systems, specialized nuclear components, TRISO/HALEU fuel and medical isotopes — a defense-grade cash engine, NOT a pre-revenue story. $8.65B backlog (+50% YoY), guided ~13%/17% rev/EPS CAGRs 2025-28, funded by U.S. Navy submarine propulsion. The Army microreactor + TRISO-fuels-Antares-to-criticality optionality is upside you didn't pay a pure-play SMR multiple for. ~$18B mcap; the quality-compounder twin to CCJ.
Earnings, margins, COGS & capex
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~86¢ is cost of goods and ~0¢ operating expense, leaving ~14¢ of operating profit.
Revenue trend
Margins
Reported financials — SEC EDGAR
Audited GAAP figures pulled from SEC filings · latest filing 2026-02-23. The audited primary-source spine — not financial advice.
Revenue — annual (GAAP)
Margins & balance sheet — FY’25
Bull & bear
A backlog-derisked, monopoly-adjacent nuclear supplier riding both a defense supercycle (submarine/carrier buildout, AUKUS) and a once-in-a-generation commercial nuclear revival (SMRs, microreactors, advanced fuel) — with record $8.65B backlog giving multi-year revenue visibility and a raised 2026 guide.
- Sole-source US naval reactor maker: BWXT is the only manufacturer of nuclear reactors for US Navy submarines and aircraft carriers — a near-impenetrable, security-cleared monopoly. ~$2.6B of Naval Nuclear Propulsion Program awards in 2025 (Virginia/Columbia-class subs, Ford-class carriers); AUKUS + additional Columbias make the program 'more robust' (Q1'26 call).
- Record backlog of $8.65B at Q1 2026, up 77% YoY and 19% sequentially — among the highest visibility in the defense/industrial complex; FY2026 guidance raised across the board (rev >$3.75B, non-GAAP EPS $4.60–4.75, adj EBITDA $650–665M).
- Only at-scale TRISO fuel producer: management states BWXT is 'the only producer of TRISO at any scale' (hundreds of kg/year), positioned to supply X-energy, the microreactor fleet, and HALEU-consortium demand — a structural choke point in the advanced-fuel value chain.
- Commercial nuclear inflecting: Commercial Operations revenue +121% YoY in Q1 2026; reactor-vessel supplier for GE Hitachi BWRX-300 SMR in Canada, positioned for the announced ~$40B / up-to-3GW Southeast US SMR buildout.
- Medical isotopes compounding: ~20% CAGR over three years, high-teens growth guided; Tc-99 generator line in late-stage commercialization (upside not yet in 2026 guidance).
- PCG acquisition (~$200M, ~$125M 2025 revenue, ~500k sq ft, 400+ workers) adds scarce domestic heavy-nuclear-component capacity — accretive and not in current guidance.
A premium-multiple, capital-intensive government contractor whose growth narrative is increasingly priced in: ~41x forward earnings for a low-double-digit organic grower exposed to federal budget timing, naval program execution, and a commercial nuclear thesis that is still early and lumpy.
- Rich valuation: ~52x trailing / ~41–43x forward P/E and ~$18B market cap leave little margin of safety; the stock prices in flawless execution of the defense supercycle and a commercial nuclear ramp that is still nascent. Trades above peer-average P/E.
- Heavy customer concentration on the US government / Naval Nuclear Propulsion Program — exposed to defense-budget timing, continuing resolutions, contract re-competes, and cost-plus margin caps. Government Ops grew only ~4% in Q1 2026 (the steady, not the exciting, half).
- Rising capital intensity compresses near-term FCF conversion: simultaneous Cambridge expansion and a new Mount Vernon greenfield (~2x Cambridge capex, 2–3 yr build) plus the ~$200M PCG deal — growth requires sustained heavy investment.
- Leverage stepped up: ~$2.0B long-term debt incl. a $1.25B convertible (dilution risk on conversion), net debt ~$1.5B — less balance-sheet cushion if a program slips or commercial demand stalls.
- Commercial nuclear is the swing factor but remains lumpy and execution/permitting-gated: SMR/microreactor revenue can be choppy (FY2025 saw lower microreactor revenue), and Tc-99 + large-scale TRISO (Wyoming) upside is real but not yet de-risked or in guidance.
- Much of the commercial bull case depends on third-party SMR deployment timelines (GE Hitachi, X-energy, utilities) that BWXT does not control — a delay in the customer's reactor schedule defers BWXT's component/fuel revenue.
What it is worth
Forward earnings multiple cross-checked vs EV/EBITDA on FY2026 raised guidance. Base on FY2026 non-GAAP EPS midpoint ~$4.68 and adj EBITDA midpoint ~$657M; ~$18.1B market cap, ~$2.0B debt, ~$0.5B cash → EV ~$19.6B.
~$150–175
multiple compression to ~32–37x forward if growth normalizes to government-led mid-single digits, capex pressures FCF, or a naval/commercial program slips; near/below the analyst low of $200
~$215–225 (≈46–48x FY2026 non-GAAP EPS ~$4.68 / EV ~30x adj EBITDA — a premium but consistent with sole-source naval moat + commercial nuclear optionality; roughly analyst consensus ~$235 average target). Current ~$198 sits modestly below consensus.
~$280–290 (analyst high)
if commercial nuclear (SMR components, Tc-99, large-scale TRISO) inflects and PCG accretion compounds, sustaining 50x+ on rising estimates
Premium multiple (~41–43x fwd, ~52x trailing) above peer average is the central debate. Quality of the naval moat + backlog visibility justifies a premium; the question is how much commercial-nuclear upside is already priced. Consensus 'Buy', avg target ~$235 (range $200–$290), ~17% above spot as of Jun 2026.
SWOT
Strengths
- Sole-source US naval nuclear reactor & fuel supplier — security-cleared, multi-decade monopoly with the Naval Nuclear Propulsion Program
- Record $8.65B backlog (Q1 2026, +77% YoY) gives rare multi-year revenue visibility
- Profitable and cash-generative (FY2025 net income $329.9M, FCF guide $315–330M for 2026) — unlike most pure-play nuclear newcomers
- Only at-scale TRISO fuel producer; HALEU consortium member — structural position in advanced-fuel supply chain
- Diversified across defense (naval, microreactor), commercial nuclear components, fuel handling, and medical isotopes
Weaknesses
- Heavy revenue concentration on US government / single naval program — budget- and re-compete-exposed
- Cost-plus contract mix caps margin upside on the government side
- Rising capex intensity (Cambridge + Mount Vernon greenfield) pressures near-term FCF conversion
- Net debt ~$1.5B incl. a $1.25B convertible (conversion dilution risk)
- Commercial/microreactor revenue is lumpy and can decline quarter-to-quarter (FY2025 lower microreactor revenue)
Opportunities
- Submarine/carrier buildout + AUKUS expands the naval propulsion addressable program
- Commercial SMR wave (GE Hitachi BWRX-300 — ~$40B / up-to-3GW Southeast US plan) — reactor-vessel and component demand
- Tc-99 generator commercialization (upside not in guidance) and ~20% medical-isotope CAGR
- Large-scale TRISO/HALEU expansion (brownfield/greenfield Wyoming) as microreactor fleet scales
- Microreactor programs (Project Pele / Army Janus, DRACO space reactor) and PCG-enabled commercial component capacity
Threats
- Federal budget gridlock / continuing resolutions delaying naval & DOE awards
- SMR/microreactor deployment timelines slipping at third-party customers (X-energy, utilities) defer BWXT revenue
- Multiple compression if the priced-in growth narrative disappoints (~41x fwd P/E)
- Competition in medical isotopes (NorthStar, Curium, Lantheus, ITM) and enrichment/fuel (Centrus, Cameco/GLE)
- Execution/cost-overrun risk on simultaneous large capacity expansions
Moats, dependencies & bottlenecks
Moats
Sole-source US naval nuclear reactor & fuel supplier (security-cleared, decades-long incumbency) Effectively a regulated monopoly; replacement would require a national security-cleared facility build — practically prohibitive
Hundreds of kg/yr today; a choke point in the advanced-fuel chain as microreactors scale
Multi-year visibility; switching costs high once designed-in
Mount Vernon, PCG) Scarce domestic capacity; barriers are capital + qualification, not absolute
Regulatory/qualification barriers in medical isotopes & nuclear fuel FDA/NRC clearances slow entry but competitors exist (Lantheus, NorthStar, Centrus)
Dependencies
US federal defense + energy budgets (Naval Nuclear Propulsion Program) customer/regulatory Largest revenue source; continuing resolutions and re-competes can delay awards/cash timing
X-energy, utilities) customer/execution Commercial component/fuel revenue gated by customers' reactor schedules BWXT doesn't control
Advanced-fuel ramp depends on upstream enrichment availability
Skilled nuclear-manufacturing labor and capacity buildout (Cambridge, Mount Vernon, PCG) operational/capital Simultaneous large expansions; execution and labor-availability risk
Conversion could dilute; refinancing exposure if rates/credit tighten
Bottlenecks
- Domestic nuclear-grade heavy-component manufacturing capacity — addressed by Cambridge expansion, Mount Vernon greenfield, and the PCG acquisition
- Skilled, security-cleared nuclear manufacturing workforce
- TRISO/HALEU fuel production scale (current hundreds of kg/yr; Wyoming brownfield/greenfield needed to scale)
- Federal appropriations and contract-award timing throttling near-term revenue recognition
- Capex/FCF tension while funding multiple simultaneous expansions
Top signals & trends
Top signals
Among the strongest visibility in defense/industrials; bookings strong in both segments
Raised one quarter into the year; PCG contribution not yet included (additional upside)
EPS +22% YoY, adj EBITDA +14%; commercial +121%
Reflects Kinectrics, nuclear components, fuel and medical inflection — the commercial thesis turning real
Structural moat; program described as 'more robust' on Q1'26 call
Prices in flawless execution; limited margin of safety
Near-term FCF conversion pressure; conversion dilution risk
Steady but budget-timing-exposed; the slower half vs commercial
Accretive, scarce capacity, not in current guidance
Trends
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
US HALEU enrichment scale-up; upstream feed for advanced fuel BWXT fabricates
Uranium supply / fuel-cycle upstream; Westinghouse co-owner
Nuclear-grade forgings, special materials; PCG acquisition internalizes some heavy-component supply
US Navy / Naval Nuclear Propulsion Program (Dept. of Defense + NNSA) Anchor customer for naval reactors/fuel; Virginia/Columbia subs, Ford carriers, AUKUS
Special materials, microreactor (Project Pele/Janus), TRISO, downblending
SMR reactor-vessel/component customer (Canada Darlington; future US)
TRISO fuel offtake for Xe-100 HTGR fleet
Utilities / nuclear operators (CANDU fleet via Kinectrics) Commercial fuel handling, components, field services, life-extension
Hospitals / radiopharma distributors (medical isotopes) Tc-99/Mo-99 generator and isotope customers
Sole US naval nuclear reactor/fuel supplier; reference point — no direct competitor in naval propulsion
US HALEU enrichment leader; overlaps/complements BWXT in advanced-fuel value chain (enrichment vs fabrication)
Uranium miner + GLE enrichment + ~49% Westinghouse stake; upstream value-chain peer, partners with GE Hitachi on BWRX-300 fuel
Pure-play SMR developer; competes for the commercial SMR narrative though BWXT supplies components rather than designs reactors
Microreactor developer (Aurora); DOE pilot, HALEU consortium member — potential fuel customer and microreactor-narrative competitor
SMR designer; BWXT is a reactor-vessel/component supplier to its BWRX-300 — customer-competitor depending on scope
Medical-isotope / radiopharma leader; competes in the diagnostic-isotope adjacency to BWXT's Tc-99/medical business
Private; Mo-99/Tc-99 supply competitor to BWXT Medical
Private/European; isotope-supply competitors in Tc-99 and therapeutic isotopes
Private; TRISO-fueled HTGR developer — both a TRISO customer and a potential fuel-fabrication competitor over time